Need professional-grade analysis? Visit stockanalysis.com
$18.77B
N/A
1,035
N/A
Hybio Pharmaceutical (300199) trades on SHE in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY21.25, up 1.43% from the previous close.
Over the past year, 300199 has traded between a low of CNY13.62 and a high of CNY29.95. The stock has gained 49.9% over this period. It is currently 29.0% below its 52-week high.
Hybio Pharmaceutical has a market capitalization of $18.77B.
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases; digestive system diseases; neoplasms; nervous system diseases; pregnancy, childbirth, and puerperium; musculoskeletal system and connective tissue diseases; infectious and parasitic diseases; circulatory system diseases; blood and hematopoietic organ diseases; and genitourinary system diseases, as well as factors influencing health status. It also provides contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates. In addition, the company engages in the provision of property services. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Wuhan, China.
Side-by-side comparison against top Healthcare peers.